Trastuzumab, which targets the HER2 protein and thus inactivates the downstream signal pathway, has been demonstrated to significantly reduce the possibility of tumor relapse by 50% in patients with HER2 positive breast cancer after complete resection5, 6, 7. Here, ERBB2 is linked to breast carcinoma.